

This listing of claims reflects the current version of the claims pending in the application. No new amendments have been introduced in this listing.

**Listing of Claims:**

1.-36. (cancelled)

37. (previously presented) A method of inhibiting the pathological proliferation of ovarian cancer cells in a patient, the method comprising:  
detecting the presence of an amplification of PIK3CA in ovarian cancer cells from the patient; and  
administering a therapeutically effective dose of an inhibitor of PI3 kinase to the patient, wherein the inhibitor inhibits PI3 kinase enzymatic activity.

38. (previously presented) The method of claim 37, wherein the inhibitor of PI3 kinase is a non-peptidic inhibitor of PI3 kinase phosphoinositide phosphorylation activity.

39. (previously presented) The method of claim 38, wherein the non-peptidic inhibitor is LY294002.

40. (cancelled)